Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease

Abstract Introduction Solanezumab is a humanized monoclonal antibody that preferentially binds to soluble amyloid β and promotes its clearance from the brain in preclinical studies. The objective of this study was to assess the effect of solanezumab in slowing global and anatomically localized brain...

Full description

Saved in:
Bibliographic Details
Main Authors: Adam J. Schwarz, Karen L. Sundell, Arnaud Charil, Michael G. Case, Ralf K. Jaeger, David Scott, Luc Bracoud, Joonmi Oh, Joyce Suhy, Michael J. Pontecorvo, Bradford C. Dickerson, Eric R. Siemers
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
Online Access:https://doi.org/10.1016/j.trci.2019.05.007
Tags: Add Tag
No Tags, Be the first to tag this record!